Merck & Co pulls $2.5 billion/year blockbuster drug Vioxx on safety fears

3 October 2004

In a move that depressed the US stock market and drug shares in particular on September 30, when drug major Merck & Co announced the voluntary worldwide withdrawal of Vioxx (rofecoxib), its blockbuster arthritis and acute pain agent which achieved worldwide sales of $2.5 billion in 2003. The company's decision, which it said is effective immediately, is based on new data from a prospective, randomized, placebo-controlled clinical evaluation, the APPROVe (Adenomatous Polyp Prevention on Vioxx) trial.

The study, which is being stopped, was designed to evaluate the efficacy of Vioxx 25mg in preventing recurrence of colorectal polyps in patients with a history of colorectal adenomas. In this trial, there was an increased relative risk for confirmed cardiovascular events, such as heart attack and stroke, beginning after 18 months of treatment in the patients taking the drug compared to those given placebo. The results for the first 18 months of the APPROVe study did not show any increased risk of confirmed cardiovascular events on Vioxx and, in this respect, are similar to the results of two placebo-controlled studies described in the current US labeling for the drug, the firm noted.

"We are taking this action because we believe it best serves the interests of patients," said Merck's chief executive, Raymond Gilmartin, who added: "although we believe it would have been possible to continue to market Vioxx with labeling that would incorporate these new data, given the availability of alternative therapies, and the questions raised by the data, we concluded that a voluntary withdrawal is the responsible course to take."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight